In addition, glycosylphosphatidylinositol (GPI) anchor peptides, inherently enriched on the exosomal membrane, have been fused with anti-EGFR nanobodies to facilitate targeting to cancer cells [165,166]. The gene discussed is EGFR; the disease is cancer.